Without robust animal, cellular, or translational models, the mechanisms by which Aβ oligomers trigger p-Tau induction and neuronal death have remained elusive; there are currently no approved disease-modifying treatments for AD despite 40 years of intense research efforts. This evidence concerns the gene MAPT and Alzheimer disease.